Zimmer Biomet Holdings, Inc. (ZBH) fair value analysis

S&P 500 · Updated 2026-09-07

Zimmer Biomet Holdings, Inc. is a global medical device company that designs, manufactures, and markets orthopedic implants, surgical products, and related technologies for joint replacement, trauma, spine, and other orthopedic procedures. The company operates in multiple countries across North America, Europe, Asia Pacific, and other international markets.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, ZBH is trading at a 10–25% discount to estimated fair value.

ZBH currently ranks #39 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $98.07
Sector: Healthcare
12-month range: $82.90–$100.56

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Momentum grade: B
Leverage: Moderate
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for ZBH

Our model validated 17 trailing price-to-earnings windows for ZBH, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $82.90–$100.56.
The 14-day relative strength index sits at a neutral 47.
3 of the last 12 weekly snapshots showed positive price momentum.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ZBH
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ZBH news

TickrTrends' derived news-sentiment signal for ZBH is currently leaning positive, computed from recent coverage.

Zimmer Biomet: Showing Signs Of Life (NYSE:ZBH) (seekingalpha.com, 2026-09-01)
TickrTrends take: Zimmer Biomet operates in the Healthcare sector and is currently assessed as undervalued by TickrTrends. The headline suggesting the company is showing signs of life may signal operational improvements or recovery that could support the undervaluation thesis if the market has not yet fully priced in these positive developments. Valuation-focused readers should monitor whether improved business momentum translates into financial results that justify closing the gap between current market price and intrinsic value estimates.
Are Wall Street Analysts Bullish on Zimmer Biomet Stock? (finance.yahoo.com, 2026-08-14)
TickrTrends take: Zimmer Biomet operates in the Healthcare sector where valuation metrics can shift significantly based on analyst sentiment and near-term clinical or commercial developments. TickrTrends currently derives an Undervalued verdict for ZBH, suggesting the market may not yet be fully pricing in positive analyst perspectives if those views are indeed bullish. For valuation-focused investors, monitoring whether analyst upgrades and price target increases can narrow the gap between the current market price and fundamental valuation estimates would be an important dynamic to track.
Zimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcript (seekingalpha.com, 2026-08-05)
TickrTrends take: Zimmer Biomet Holdings operates in the Healthcare sector where earnings performance directly informs valuation multiples and investor confidence in the company's growth trajectory. TickrTrends currently derives an Undervalued verdict for ZBH, suggesting the market may not be fully pricing in the company's earnings power relative to peers. Investors monitoring the company's valuation should track how Q2 2026 results and forward guidance influence the gap between current market pricing and intrinsic value assessments.

What people are saying

Follow the ZBH conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ZBH stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ZBH is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is ZBH's TickrTrends verdict?

ZBH's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does ZBH compare to other Healthcare stocks?

ZBH ranks #39 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ZBH overbought or oversold?

ZBH's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ZBH vs ABT · ZBH vs CI · ZBH vs COLL · ZBH vs DVA · ZBH vs INCY